1. Home
  2. MIN vs BNR Comparison

MIN vs BNR Comparison

Compare MIN & BNR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo MFS Intermediate Income Trust

MIN

MFS Intermediate Income Trust

HOLD

Current Price

$2.48

Market Cap

279.9M

Sector

Finance

ML Signal

HOLD

Logo Burning Rock Biotech Limited

BNR

Burning Rock Biotech Limited

N/A

Current Price

$16.16

Market Cap

252.7M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
MIN
BNR
Founded
1988
2014
Country
United States
China
Employees
N/A
N/A
Industry
Trusts Except Educational Religious and Charitable
Medical Specialities
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
279.9M
252.7M
IPO Year
N/A
2019

Fundamental Metrics

Financial Performance
Metric
MIN
BNR
Price
$2.48
$16.16
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
398.1K
29.9K
Earning Date
01-01-0001
03-12-2026
Dividend Yield
7.31%
N/A
EPS Growth
N/A
N/A
EPS
0.08
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$111.65
Revenue Next Year
N/A
N/A
P/E Ratio
$31.88
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.44
$2.18
52 Week High
$2.72
$41.72

Technical Indicators

Market Signals
Indicator
MIN
BNR
Relative Strength Index (RSI) 45.92 35.24
Support Level N/A $15.61
Resistance Level $2.60 $23.42
Average True Range (ATR) 0.03 1.24
MACD 0.01 0.19
Stochastic Oscillator 34.64 4.49

Price Performance

Historical Comparison
MIN
BNR

About MIN MFS Intermediate Income Trust

MFS Intermediate Income Trust is a diversified closed-end management investment company. The fund's investment objective is to seek high current income but may also consider capital appreciation. It invests the assets in debt instruments. Its portfolio of investments comprises different sector investments such as the automotive, chemicals, energy, food and beverages, insurance, and other sectors.

About BNR Burning Rock Biotech Limited

Burning Rock Biotech Ltd is a cancer diagnostics company. It is a NGS-based cancer therapy selection company. Its cancer therapy selection platform is built upon advanced proprietary technologies, comprehensive portfolio of products and a two-pronged market-driven commercial infrastructure addressing both larger hospitals through company's in-hospital model and smaller hospitals through its central laboratory model. It had three operating segments, including Central laboratory business, In-hospital business and Pharma research and development services. It generates the majority of its revenue from Central laboratory business. Its products are Pan-HEME, OncoScreen-WES, brPROPHET, OncoScreen Plus, and others.

Share on Social Networks: